These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 36399712)

  • 1. A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.
    Rao VK; Webster S; Šedivá A; Plebani A; Schuetz C; Shcherbina A; Conlon N; Coulter T; Dalm VA; Trizzino A; Zharankova Y; Kulm E; Körholz J; Lougaris V; Rodina Y; Radford K; Bradt J; Kucher K; Relan A; Holland SM; Lenardo MJ; Uzel G
    Blood; 2023 Mar; 141(9):971-983. PubMed ID: 36399712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.
    Rao VK; Webster S; Dalm VASH; Šedivá A; van Hagen PM; Holland S; Rosenzweig SD; Christ AD; Sloth B; Cabanski M; Joshi AD; de Buck S; Doucet J; Guerini D; Kalis C; Pylvaenaeinen I; Soldermann N; Kashyap A; Uzel G; Lenardo MJ; Patel DD; Lucas CL; Burkhart C
    Blood; 2017 Nov; 130(21):2307-2316. PubMed ID: 28972011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim analysis: Open-label extension study of leniolisib for patients with APDS.
    Rao VK; Kulm E; Šedivá A; Plebani A; Schuetz C; Shcherbina A; Dalm VA; Trizzino A; Zharankova Y; Webster S; Orpia A; Körholz J; Lougaris V; Rodina Y; Radford K; Bradt J; Relan A; Holland SM; Lenardo MJ; Uzel G
    J Allergy Clin Immunol; 2024 Jan; 153(1):265-274.e9. PubMed ID: 37797893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3Kδ Pathway Dysregulation and Unique Features of Its Inhibition by Leniolisib in Activated PI3Kδ Syndrome and Beyond.
    Cant AJ; Chandra A; Munro E; Rao VK; Lucas CL
    J Allergy Clin Immunol Pract; 2024 Jan; 12(1):69-78. PubMed ID: 37777067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with selective PI3Kδ inhibitor leniolisib in adults with activated PI3Kδ syndrome.
    Rao VK; Kulm E; Grossman J; Buchbinder D; Chong H; Bradt J; Webster S; Šedivá A; Dalm VA; Uzel G
    Blood Adv; 2024 Jun; 8(12):3092-3108. PubMed ID: 38593221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APDS patients with immune-complex vasculitis and resolution with leniolisib.
    Doroudchi MA; Stephens AV; Wang Z; Dhami J; Butte MJ
    Clin Immunol; 2024 May; 262():110176. PubMed ID: 38462154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leniolisib: First Approval.
    Duggan S; Al-Salama ZT
    Drugs; 2023 Jul; 83(10):943-948. PubMed ID: 37256490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulating the PI3K Signalling Pathway in Activated PI3K Delta Syndrome: a Clinical Perspective.
    Berglund LJ
    J Clin Immunol; 2023 Dec; 44(1):34. PubMed ID: 38148368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.
    Jamee M; Moniri S; Zaki-Dizaji M; Olbrich P; Yazdani R; Jadidi-Niaragh F; Aghamahdi F; Abolhassani H; Condliffe AM; Aghamohammadi A; Azizi G
    Clin Rev Allergy Immunol; 2020 Dec; 59(3):323-333. PubMed ID: 31111319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ANCA vasculitis expands the spectrum of autoimmune manifestations of activated PI3 kinase δ syndrome.
    Sood AK; Francis O; Schworer SA; Johnson SM; Smith BD; Googe PB; Wu EY
    Front Pediatr; 2023; 11():1179788. PubMed ID: 37274825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated phosphoinositde 3-kinase (PI3Kδ) syndrome: an Italian point of view on diagnosis and new advances in treatment.
    Lougaris V; Piane FL; Cancrini C; Conti F; Tommasini A; Badolato R; Trizzino A; Zecca M; De Rosa A; Barzaghi F; Pignata C
    Ital J Pediatr; 2024 May; 50(1):103. PubMed ID: 38769568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homeostatic and pathogenic roles of PI3Kδ in the human immune system.
    Sogkas G; Adriawan IR; Dubrowinskaja N; Atschekzei F; Schmidt RE
    Adv Immunol; 2020; 146():109-137. PubMed ID: 32327151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy.
    Michalovich D; Nejentsev S
    Front Immunol; 2018; 9():369. PubMed ID: 29535736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD.
    Cahn A; Hamblin JN; Begg M; Wilson R; Dunsire L; Sriskantharajah S; Montembault M; Leemereise CN; Galinanes-Garcia L; Watz H; Kirsten AM; Fuhr R; Hessel EM
    Pulm Pharmacol Ther; 2017 Oct; 46():69-77. PubMed ID: 28823947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies.
    Diaz N; Juarez M; Cancrini C; Heeg M; Soler-Palacín P; Payne A; Johnston GI; Helmer E; Cain D; Mann J; Yuill D; Conti F; Di Cesare S; Ehl S; Garcia-Prat M; Maccari ME; Martín-Nalda A; Martínez-Gallo M; Moshous D; Santilli V; Semeraro M; Simonetti A; Suarez F; Cavazzana M; Kracker S
    J Immunol; 2020 Dec; 205(11):2979-2987. PubMed ID: 33115853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
    Juarez M; Diaz N; Johnston GI; Nayar S; Payne A; Helmer E; Cain D; Williams P; Devauchelle-Pensec V; Fisher BA; Giacomelli R; Gottenberg JE; Guggino G; Kvarnström M; Mariette X; Ng WF; Rosas J; Sánchez Bursón J; Triolo G; Barone F; Bowman SJ
    Rheumatology (Oxford); 2021 Mar; 60(3):1364-1375. PubMed ID: 32949140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib.
    De Buck S; Kucher K; Hara H; Gray C; Woessner R
    Biopharm Drug Dispos; 2018 Sep; 39(8):394-402. PubMed ID: 30171694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome.
    Begg M; Amour A; Jarvis E; Tang T; Franco SS; Want A; Beerahee M; Fernando D; Karkera Y; Sander C; Southworth T; Singh D; Clark J; Nejentsev S; Okkenhaug K; Condliffe A; Chandra A; Cahn A; Hall EB
    Pulm Pharmacol Ther; 2023 Apr; 79():102201. PubMed ID: 36841351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.
    Asano T; Okada S; Tsumura M; Yeh TW; Mitsui-Sekinaka K; Tsujita Y; Ichinose Y; Shimada A; Hashimoto K; Wada T; Imai K; Ohara O; Morio T; Nonoyama S; Kobayashi M
    Front Immunol; 2018; 9():568. PubMed ID: 29675019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
    Condliffe AM; Chandra A
    Front Immunol; 2018; 9():338. PubMed ID: 29556229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.